...
首页> 外文期刊>Journal of enzyme inhibition and medicinal chemistry. >Design, synthesis and molecular docking of novel diarylcyclohexenone and diarylindazole derivatives as tubulin polymerization inhibitors
【24h】

Design, synthesis and molecular docking of novel diarylcyclohexenone and diarylindazole derivatives as tubulin polymerization inhibitors

机译:作为微管蛋白聚合抑制剂的新型二芳基环己烯酮和二芳基吲唑衍生物的设计,合成和分子对接

获取原文

摘要

Abstract New target compounds were designed as inhibitors of tubulin polymerization relying on using two types of ring B models (cyclohexenone and indazole) to replace the central ring in colchicine. Different functional groups (R1) were attached to manipulate their physicochemical properties and/or their biological activity. The designed compounds were assessed for their antitumor activity on HCT-116 and MCF-7 cancer cell lines. Compounds 4b , 5e and 5f exhibited comparable or higher potency than colchicine against colon HCT-116 and MCF-7 tumor cells. The mechanism of the antitumor activity was investigated through evaluating the tubulin inhibition potential of the active compounds. Compounds 4b , 5e and 5f showed percentage inhibition of tubulin in both cell line homogenates ranging from 79.72% to 89.31%. Cell cycle analysis of compounds 4b , 5e and 5f revealed cell cycle arrest at G2/M phase. Molecular docking revealed the binding mode of these new compounds into the colchicine binding site of tubulin.
机译:摘要依靠使用两种类型的环B模型(环己烯酮和吲唑)取代秋水仙碱的中心环,设计了新的目标化合物作为微管蛋白聚合抑制剂。连接不同的官能团(R 1 )以控制其理化性质和/或生物活性。评估设计的化合物对HCT-116和MCF-7癌细胞的抗肿瘤活性。与秋水仙碱相比,化合物4b,5e和5f对结肠HCT-116和MCF-7肿瘤细胞表现出相当或更高的效力。通过评估活性化合物的微管蛋白抑制潜能,研究了抗肿瘤活性的机制。化合物4b,5e和5f在两种细胞系匀浆中均显示出微管蛋白的抑制百分比,范围为79.72%至89.31%。化合物4b,5e和5f的细胞周期分析表明,细胞周期停滞在G 2 / M期。分子对接揭示了这些新化合物与微管蛋白秋水仙碱结合位点的结合方式。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号